FMP

FMP

Enter

OPT - Opthea Limited

Financial Summary of Opthea Limited(OPT), Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies pr

photo-url-https://financialmodelingprep.com/image-stock/OPT.png

Opthea Limited

OPT

NASDAQ

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

2.13 USD

0.04 (1.88%)

About

ceo

Dr. Frederic Guerard M.S., Pharm.D.

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the trea...

CIK

0001815620

ISIN

US68386J2087

CUSIP

68386J208

Address

650 Chapel Street

Phone

61 3 9826 0399

Country

AU

Employee

24

IPO Date

Oct 16, 2020

Summary

CIK

0001815620

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

68386J208

ISIN

US68386J2087

Country

AU

Price

2.13

Beta

0.77

Volume Avg.

23.16k

Market Cap

304.49M

Shares

-

52-Week

1.6-4.4

DCF

1.01

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-0.96

P/B

-

Website

https://www.opthea.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest OPT News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep